Evidence map›Paper›PMID 25848765›Full record

ArticlePloS one2015

High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival.

Maj Rabjerg, Aida Oliván-Viguera, Lars Koch Hansen, Line Jensen, Linda Sevelsted-Møller, Steen Walter, Boye L Jensen, Niels Marcussen, Ralf Köhler

Open access · goldAbstract readClinical Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Imaging of KChemMedChem · 2023
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Ion Channels in Cancer: Orchestrators of Electrical Signaling and Cellular Crosstalk.Reviews of physiology, biochemistry and pharmacology · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Membrane Transporters and Channels in Melanoma.Reviews of physiology, biochemistry and pharmacology · 2021
    Review
  18. Review
  19. Co-staining of KChemMedChem · 2020
    Article
  20. Aging · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Maj RabjergDepartment of Pathology, Odense University Hospital, DK-5000 Odense C, Denmark.
Aida Oliván-VigueraAragon Institute of Health Sciences I+CS/IIS, 50009 Zaragoza, Spain.
Lars Koch HansenDepartment of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense C, Denmark.
Line JensenDepartment of Pathology, Odense University Hospital, DK-5000 Odense C, Denmark.
Linda Sevelsted-MøllerDepartment of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense C, Denmark.
Steen WalterDepartment of Urology, Odense University Hospital, DK-5000 Odense C, Denmark.
Boye L JensenDepartment of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense C, Denmark.
Niels MarcussenDepartment of Pathology, Odense University Hospital, DK-5000 Odense C, Denmark.
Ralf KöhlerAragon Institute of Health Sciences I+CS/IIS, 50009 Zaragoza, Spain; Fundación Agencia Aragonesa para la Investigación y Desarrollo (ARAID), 50009 Zaragoza, Spain.
Odense University Hospital · DKUniversity of Southern Denmark · DKInstituto de Investigación Sanitaria Aragón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCa2+-activated K+ channels have been implicated in cancer cell growth, metastasis, and tumor angiogenesis. Here we hypothesized that high mRNA and protein expression of the intermediate-conductance Ca2+-activated K+ channel, KCa3.1, is a molecular marker of clear cell Renal Cell Carcinoma (ccRCC) and metastatic potential and survival. METHODOLOGY/PRINCIPAL

findingsWe analyzed channel expression by qRT-PCR, immunohistochemistry, and patch-clamp in ccRCC and benign oncocytoma specimens, in primary ccRCC and oncocytoma cell lines, as well as in two ccRCC cell lines (Caki-1 and Caki-2). CcRCC specimens contained 12-fold higher mRNA levels of KCa3.1 than oncocytoma specimens. The large-conductance channel, KCa1.1, was 3-fold more highly expressed in ccRCC than in oncocytoma. KCa3.1 mRNA expression in ccRCC was 2-fold higher than in the healthy cortex of the same kidney. Disease specific survival trended towards reduction in the subgroup of high-KCa3.1-expressing tumors (p<0.08 vs. low-KCa3.1-expressing tumors). Progression-free survival (time to metastasis/recurrence) was reduced significantly in the subgroup of high-KCa3.1-expressing tumors (p<0.02, vs. low-KCa3.1-expressing tumors). Immunohistochemistry revealed high protein expression of KCa3.1 in tumor vessels of ccRCC and oncocytoma and in a subset of ccRCC cells. Oncocytoma cells were devoid of KCa3.1 protein. In a primary ccRCC cell line and Caki-1/2-ccRCC cells, we found KCa3.1-protein as well as TRAM-34-sensitive KCa3.1-currents in a subset of cells. Furthermore, Caki-1/2-ccRCC cells displayed functional Paxilline-sensitive KCa1.1 currents. Neither KCa3.1 nor KCa1.1 were found in a primary oncocytoma cell line. Yet KCa-blockers, like TRAM-34 (KCa3.1) and Paxilline (KCa1.1), had no appreciable effects on Caki-1 proliferation in-vitro. CONCLUSIONS/SIGNIFICANCE: Our study demonstrated expression of KCa3.1 in ccRCC but not in benign oncocytoma. Moreover, high KCa3.1-mRNA expression levels were indicative of low disease specific survival of ccRCC patients, short progression-free survival, and a high metastatic potential. Therefore, KCa3.1 is of prognostic value in ccRCC.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedCarcinoma, Renal CellCell Line, TumorDisease-Free SurvivalFemaleHumansIntermediate-Conductance Calcium-Activated Potassium ChannelsKidney NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm ProteinsSurvival RateIntermediate-Conductance Calcium-Activated Potassium ChannelsKCNN4 protein, humanNeoplasm Proteins

Identifiers

PMID25848765
PMCPMC4388734
OpenAlexW2009543765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.